Jope, 1999 - Google Patents
Cholinergic muscarinic receptor signaling by the phosphoinositide signal transduction system in Alzheimer's diseaseJope, 1999
- Document ID
- 16453596383032801737
- Author
- Jope R
- Publication year
- Publication venue
- Journal of Alzheimer’s Disease
External Links
Snippet
Recent years have seen the advent of new methods capable of measuring the activity of receptor-coupled, G-protein-mediated, phosphoino-sitide second messenger production in membranes prepared from postmortem human brain. Considering the interest in treating …
- 206010001897 Alzheimer's disease 0 title abstract description 146
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—G01N2333/4701
- G01N2333/4709—Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pîrşcoveanu et al. | Tau protein in neurodegenerative diseases-a review | |
| US9188595B2 (en) | Alzheimer's disease diagnosis based on mitogen-activated protein kinase phosphorylation | |
| Lee | Disruption of the cytoskeleton in Alzheimer's disease | |
| Pacheco et al. | Phosphoinositide signaling in human brain | |
| Sergeant et al. | Tau protein as a differential biomarker of tauopathies | |
| Halliday et al. | Neuropathology underlying clinical variability in patients with synucleinopathies | |
| Pointer et al. | Cardiolipin in central nervous system physiology and pathology | |
| Giacomini et al. | A new TAO kinase inhibitor reduces tau phosphorylation at sites associated with neurodegeneration in human tauopathies | |
| Jing et al. | Altered subcellular distribution of c-Abl in Alzheimer's disease | |
| Gong et al. | Dysregulation of protein phosphorylation/dephosphorylation in Alzheimer′ s disease: a therapeutic target | |
| Cárdenas-Aguayo et al. | Physiological role of amyloid beta in neural cells: the cellular trophic activity | |
| US20130123133A1 (en) | Screening methods | |
| Grimm et al. | Altered membrane fluidity and lipid raft composition in presenilin‐deficient cells | |
| US20240192235A1 (en) | Ceramide and spingomyelin in neurological disorders | |
| Hernández et al. | GSK-3 dependent phosphoepitopes recognized by PHF-1 and AT-8 antibodies are present in different tau isoforms | |
| Pandey et al. | Altered expression and phosphorylation of myristoylated alanine-rich C kinase substrate (MARCKS) in postmortem brain of suicide victims with or without depression | |
| Jope | Cholinergic muscarinic receptor signaling by the phosphoinositide signal transduction system in Alzheimer's disease | |
| Nitsch et al. | Regulation of proteolytic processing of the amyloid β-protein precursor of Alzheimer’s disease in transfected cell lines and in brain slices | |
| Uno et al. | Efficacy of a novel, orally active GSK-3 inhibitor 6-Methyl-N-[3-[[3-(1-methylethoxy) propyl] carbamoyl]-1H-pyrazol-4-yl] pyridine-3-carboxamide in tau transgenic mice | |
| Zhang et al. | Hydrogen sulfide-induced processing of the amyloid precursor protein in SH-SY5Y human neuroblastoma cells involves the PI3-K/Akt signaling pathway | |
| Gibb et al. | Differential involvement and heterogeneous phosphorylation of tau isoforms in progressive supranuclear palsy | |
| WO2022221559A2 (en) | Ceramide and sphingomyelin in neurological disorders | |
| Carpinteiro | Study of the neuronal molecular mechanisms in TAU uptake | |
| Tjiang | Mitochondrial Distribution and Dynamics at the Axon Initial Segment and their Influence on TAU-Trafficking | |
| Chandrol et al. | Recent Progress in Alzheimer’s Disease: Pathophysiology, Newer Natural & Synthetic Inhibitors, and Therapeutic Targets |